Acetaminophen to Prevent Ischemic Oxidative Reperfusion Injury During Percutaneous Coronary Intervention for Acute Myocardial Infarction

• Status: Withdrawn
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the hypothesis that acetaminophen will reduce lipid peroxidation and isoprostane formation during reperfusion after percutaneous revascularization for acute myocardial infarction.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanderbilt University
• Treatments: Acetaminophen

Criteria

Inclusion Criteria:

• Patients presenting with STEMI

Exclusion Criteria:

• Duration of symptoms > 12 hours

• Suspected LM or proximal LAD occlusion (based on EKG interpretation)

• Hemodynamic instability

• Acetaminophen use in prior 24 hours

• Use of dipyridamole, or Aggrenox, a formulation of aspirin and extended-release dipyridamole, within 48 hours

• Current use of the following medications: phenytoin, valproic acid, phenobarbital, topiramate, rifampin, carbamazepine, cyclophosphamide, ritonavir, efavirenz, St. John's Wort

• Chronic heavy alcohol use

• Chronic liver disease (other than non-alcoholic fatty liver infiltration)

• Severe valvular heart disease

• Stroke in the past 60 days

• Active major bleeding

• Major surgery in the past 30 days

• Ongoing treatment for active malignancy

• Life expectancy less than 12 months as determined by the patient's attending physician

• Pregnancy

• asthma or severe COPD

• active wheezing on presentation

• allergy or prior adverse reaction to adenosine